Lupin Ltd - Company Profile
Powered by
All the data and insights you need on Lupin Ltd in one report.
- Save hours of research time and resources with
our up-to-date Lupin Ltd Strategy Report
- Understand Lupin Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Lupin Ltd (Lupin) develops and manufactures generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It has expertise in the areas of cardiovascular, asthma, diabetic management, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-TB, and cephalosporins. The company undertakes extensive research and development activities of pharmaceuticals for the treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, diabetes, tuberculosis, inflammation and others. Lupin also develops value-added generic pharmaceuticals based on its platform technologies. The company along with its subsidiaries operates manufacturing facilities in India, the US, Mexico, and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.
Lupin Ltd premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Anti-Tuberculosis: Tablets and Capsules | Rcinex |
Diabetes Management: Tablets, Injections, Capsules, Insulin Cartridge and Devices | Akurit |
Cardiac Care: Tablets, Injections, Capsules and Injectables | AKT |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In May, the company partnered with Sandoz Canada and introduced Rymti, its biosimilar in Canada. |
2024 | New Products/Services | In April, the company introduced the first generic version of Oracea in the US. |
2024 | Contracts/Agreements | In April, the company entered into a partnership with Partex to improve drug discovery processes across multiple therapeutic areas. |
Competitor Comparison
Key Parameters | Lupin Ltd | Sun Pharmaceutical Industries Ltd | Dr. Reddy's Laboratories Ltd | Cipla Ltd | Divi's Laboratories Ltd |
---|---|---|---|---|---|
Headquarters | India | India | India | India | India |
City | Mumbai | Mumbai | Hyderabad | Mumbai | Hyderabad |
State/Province | Maharashtra | Maharashtra | Telangana | Maharashtra | Telangana |
No. of Employees | 18,971 | 41,000 | 24,832 | 26,615 | 16,950 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Ramesh Swaminathan | Chief Financial Officer; Head of Corporate Affairs; Director | Executive Board | 2020 | 57 |
Rakesh Bhardwaj | Chief Information Officer | Senior Management | 2024 | - |
Shahin Fesharaki | Chief Scientific Officer | Senior Management | 2022 | - |
Ranjana Pathak | Chief Quality Officer | Senior Management | 2024 | - |
Mr. Christoph Funke | Chief Technical Operations Officer | Senior Management | 2024 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer